Free Trial
NASDAQ:KROS

Keros Therapeutics (KROS) Stock Price, News & Analysis

Keros Therapeutics logo
$14.48 +0.06 (+0.42%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$14.07 -0.41 (-2.83%)
As of 08/15/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Keros Therapeutics Stock (NASDAQ:KROS)

Key Stats

Today's Range
$14.13
$14.53
50-Day Range
$13.33
$14.62
52-Week Range
$9.12
$72.37
Volume
383,521 shs
Average Volume
439,171 shs
Market Capitalization
$588.18 million
P/E Ratio
46.71
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Moderate Buy

Company Overview

Keros Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

KROS MarketRank™: 

Keros Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 591st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Keros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Keros Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Keros Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.74) to ($4.87) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Keros Therapeutics is 46.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Keros Therapeutics is 46.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.58.

  • Price to Earnings Growth Ratio

    Keros Therapeutics has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Keros Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    15.01% of the float of Keros Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Keros Therapeutics has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Keros Therapeutics has recently decreased by 4.16%, indicating that investor sentiment is improving.
  • Dividend Yield

    Keros Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Keros Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.01% of the float of Keros Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Keros Therapeutics has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Keros Therapeutics has recently decreased by 4.16%, indicating that investor sentiment is improving.
  • News Sentiment

    Keros Therapeutics has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Keros Therapeutics this week, compared to 6 articles on an average week.
  • MarketBeat Follows

    2 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Keros Therapeutics' insider trading history.
Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KROS Stock News Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
William Blair Cuts Earnings Estimates for Keros Therapeutics
See More Headlines

KROS Stock Analysis - Frequently Asked Questions

Keros Therapeutics' stock was trading at $15.83 at the beginning of 2025. Since then, KROS shares have decreased by 8.5% and is now trading at $14.48.

Keros Therapeutics, Inc. (NASDAQ:KROS) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. The company's revenue was up 49002.7% on a year-over-year basis.

Keros Therapeutics (KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Top institutional shareholders of Keros Therapeutics include Geode Capital Management LLC (2.04%), Federated Hermes Inc. (1.61%), PDT Partners LLC (0.82%) and Canada Pension Plan Investment Board (0.78%). Insiders that own company stock include Adar1 Capital Management, Llc, Carl L Gordon, Carl L Gordon and Keith Regnante.
View institutional ownership trends
.

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD).

Company Calendar

Last Earnings
8/06/2025
Today
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KROS
CIK
1664710
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$102.00
Low Price Target
$15.00
Potential Upside/Downside
+107.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.31
Trailing P/E Ratio
46.71
Forward P/E Ratio
N/A
P/E Growth
1.77
Net Income
-$187.35 million
Net Margins
8.06%
Pretax Margin
11.55%
Return on Equity
2.96%
Return on Assets
2.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.11
Quick Ratio
21.11

Sales & Book Value

Annual Sales
$3.55 million
Price / Sales
165.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$17.40 per share
Price / Book
0.83

Miscellaneous

Outstanding Shares
40,620,000
Free Float
32,248,000
Market Cap
$588.18 million
Optionable
Optionable
Beta
1.33

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:KROS) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners